Mitogen-Activated Protein Kinase Kinase 2 (MAP2K2) (pThr394) antibody

Details for Product No. ABIN196623
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

 
Antigen
Synonyms CFC4, MAPKK2, MEK2, MKK2, PRKMK2, AA589381, MK2, Prkmk2
Epitope
pThr394
(36), (12), (8), (7), (4), (3), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Reactivity
Human, Mouse (Murine)
(141), (94), (87), (13), (4), (3), (1)
Host
Rabbit
(122), (24)
Clonality
Polyclonal
Conjugate
Un-conjugated
(3), (3), (3), (3), (3), (3), (3), (3), (3), (3), (3)
Application
Immunocytochemistry (ICC), Immunofluorescence (IF), Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
(114), (45), (41), (30), (30), (23), (22), (8), (6), (4), (2), (2), (1), (1)
Pubmed 2 references available
Catalog no. ABIN196623
Quantity 50 µg
Price
286.00 $   Plus shipping costs $45.00
Shipping to United States (Change)
Availability Will be delivered in 6 to 8 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen The antiserum was produced against synthesized phosphopeptide derived from human MEK2 around the phosphorylation site of threonine 394 (P-G-TP-P-T).
Specificity MEK2 (phospho-Thr394) antibody detects endogenous levels of MEK2 only when phosphorylated at threonine 394.
Purification Immunoaffinity chromatography
Alternative Name MAPKK 2
Background Microtubule associated protein kinase kinase 2 (MEK2 or MAPKK2) is a member of a family of tyrosine/threonine protein kinases that activate the ERK 1 & 2/MAPK enzymes by phosphorylating both residues within the threonine/glutamic acid/tyrosine (TEY) motif in the activation loop. MEK 1 & 2 are also activated by dual phosphorylation, which occurs on serines 218 and 222, in the activation loop of the MEKs. Threonine 394 of MEK2 is phosphorylated by ERK 2, which serves as a negative feedback loop by suppressing activation of MEK2.
Alternate names: Dual specificity mitogen-activated protein kinase kinase 2, ERK activator kinase 2, MAP kinase kinase 2, MAP kinase kinase 2, MAPK/ERK kinase 2, MEK2, MKK2
Gene ID 5605
NCBI Accession NP_109587.1
UniProt P36507
Research Area Kinases/Phosphatases
Application Notes Suitable for use in Western blot (1: 500~1: 1000) and Immunohistochemistry (1: 50~1: 100). Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Buffer Phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl containing 0.02% Sodium Azide as preservative and 50% glycerol as stabilizer
Preservative Sodium azide
Handling Advice Avoid repeated freezing and thawing.
Storage -20 °C
Storage Comment Store the antibody (in aliquots) at -20°C.
Expiry Date 12 months
Supplier Images
anti-Mitogen-Activated Protein Kinase Kinase 2 (MAP2K2) (pThr394) antibody anti-Mitogen-Activated Protein Kinase Kinase 2 (MAP2K2) (pThr394) antibody
anti-Mitogen-Activated Protein Kinase Kinase 2 (MAP2K2) (pThr394) antibody (2) anti-Mitogen-Activated Protein Kinase Kinase 2 (MAP2K2) (pThr394) antibody (Image 2)
anti-Mitogen-Activated Protein Kinase Kinase 2 (MAP2K2) (pThr394) antibody (3) anti-Mitogen-Activated Protein Kinase Kinase 2 (MAP2K2) (pThr394) antibody (Image 3)
Background publications Crews, Alessandrini, Erikson: "The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product." in: Science (New York, N.Y.), Vol. 258, Issue 5081, pp. 478-80, 1992 (PubMed).

Alessi, Saito, Campbell et al.: "Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1." in: The EMBO journal, Vol. 13, Issue 7, pp. 1610-9, 1994 (PubMed).

Hosts (122), (24)
Reactivities (141), (94), (87), (13), (4), (3), (1)
Applications (114), (45), (41), (30), (30), (23), (22), (8), (6), (4), (2), (2), (1), (1)
Conjugates (3), (3), (3), (3), (3), (3), (3), (3), (3), (3), (3)
Epitopes (36), (12), (8), (7), (4), (3), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
back to top